Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;21(4):344-353.
doi: 10.1176/appi.focus.20230009. Epub 2023 Oct 15.

The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence

Kamyar Keramatian  1 , Nellai K Chithra  1 , Lakshmi N Yatham  1
Affiliations
Review

The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence

Kamyar Keramatian et al. Focus (Am Psychiatr Publ). 2023 Oct.

Abstract

Bipolar disorder is a complex and heterogeneous psychiatric condition that affects more than 2% of the population. The assessment and treatment of bipolar disorder can be a challenge for clinicians, given its clinical complexity and the rapidly changing treatment landscape with the growing range of treatment options that are becoming available for various phases of the illness. To help clinicians navigate the complexity involved in the assessment and management of bipolar disorder, the guidelines of the 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) synthesized the evidence on the efficacy, safety, and tolerability of treatments for bipolar disorder and translated it into first-, second-, and third-line treatment recommendations. The main objective of this contribution is to provide clinicians with a summary of the 2018 CANMAT/ISBD guideline recommendations with the addition of any new evidence for the treatment of bipolar disorder across the lifespan.

Keywords: Bipolar Disorder; Clinical Drug Studies; Evidence-Based Practice; Practice Guidelines.

PubMed Disclaimer

Conflict of interest statement

Dr. Yatham is a consultant for, has received speaker fees from, sits on the advisory board of, and/or receives research funding from AbbVie, Alkermes, Allergan, Canadian Network for Mood and Anxiety Treatments, Canadian Institutes of Health Research, Dainippon Sumitomo Pharma, Gedeon Richter, Intracellular Therapies, Lundbeck, Merck, Otsuka, Sanofi, and Sunovion over the past 3 years. Dr. Keramatian has been on an advisory board for AbbVie. Dr. Chithra reports no financial relationships with commercial interests.

References

    1. Yatham LN , Kennedy SH , Parikh SV , et al. : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder . Bipolar Disord 2018. ; 20 : 97 – 170 - PMC - PubMed
    1. Diagnostic and Statistical Manual of Mental Disorders , 5th ed . Arlington, VA: , American Psychiatric Association; , 2013.
    1. Merikangas KR , Jin R , He JP , et al. : Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative . Arch Gen Psychiatry 2011. ; 68 : 241 – 251 - PMC - PubMed
    1. Keramatian K , Pinto JV , Schaffer A , et al. : Clinical and demographic factors associated with delayed diagnosis of bipolar disorder: data from Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study . J Affect Disord 2022. ; 296 : 506 – 513 - PubMed
    1. Hirschfeld RMA , Lewis L , Vornik LA : Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder . J Clin Psychiatry 2003. ; 64 : 161 – 174 - PubMed

LinkOut - more resources